분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2013-07-16 00:07:10 , Hit : 2017
 Gene therapy using HIV helps children with fatal diseases, study says


Gene therapy researchers say they used a safe version of HIV to prevent metachromatic leukodystrophy and halt Wiskott-Aldrich syndrome in children.

Italian researchers used gene therapy to treat children with two rare genetic diseases, according to a report in the journal Science.
Italian researchers used gene therapy to treat children with two rare genetic diseases, according to a report in the journal Science. (Peter and Maria Hoey/For the Times / July 11, 2013)

Ads by Google
By Melissa Pandika

July 11, 2013, 4:16 p.m.
Italian researchers have used a defanged version of HIV to replace faulty genes — and eliminate devastating symptoms — in children suffering two rare and fatal genetic diseases.

Improved gene therapy techniques prevented the onset of metachromatic leukodystrophy in three young children and halted the progression of Wiskott-Aldrich syndrome in three others.

The advance represents a major stride for a field that has struggled to translate experimental successes in lab animals into safe and effective treatments for people, experts said. Researchers may be able to use the team's method as a template, modifying it to treat a variety of diseases.

This is "ammunition for the gene therapy world," said Dr. Theodore Friedmann, a pediatric gene therapist at UC San Diego, who was not part of the study. "The field is slowly but surely making impressive advances against … quite untreatable diseases."

The scientists published results from the two clinical trials Thursday in the journal Science.

Metachromatic leukodystrophy affects just 1 in 40,000 to 1 in 160,000 people worldwide; Wiskott-Aldrich syndrome, only 1 to 10 per million males. But both illnesses are devastating. Children with late infantile metachromatic leukodystrophy, the most common form of that disease, begin having trouble walking about a year old and soon after experience muscle deterioration, developmental delays, paralysis and dementia. Most die within a few years of onset.

Kids with Wiskott-Aldrich syndrome suffer from eczema, bruising, nosebleeds and recurrent infections. Most develop at least one autoimmune disorder. A third get cancers, such as lymphoma and leukemia. Life expectancy ranges from 15 to 20 years.

The disorders are challenging — when not impossible — to treat. No therapy exists for metachromatic leukodystrophy. A bone marrow transplant can stop disease progression for the few Wiskott-Aldrich patients with an immunologically matched sibling, but they may experience severe side effects or death if the donor is not as close a match.

Both diseases are caused by inherited genetic mutations that disrupt the body's ability to produce crucial enzymes. In each trial, researchers took the normal form of the faulty gene and attached it to a virus derived from HIV that had been modified so that it could no longer cause AIDS.

The researchers removed bone marrow stem cells from the patients and then used the lentivirus to infect those cells with the normal genes.

The rest of the process resembled a traditional bone marrow transplant, with patients receiving chemotherapy to destroy their diseased bone marrow and then receiving infusions of the modified cells, which proliferated to form new marrow. Using the patients' own cells sidesteps problems of donor incompatibility.

The team treated the three metachromatic leukodystrophy patients before symptoms of the disorder had appeared. The kids stayed almost entirely symptom-free during the trial, up to two years after treatment. Gene therapy arrested the progression of disease in the Wiskott-Aldrich syndrome patients over up to two and a half years of follow-up.

Looking at the patients' bone marrow stem cells, the researchers found that 45% to 80% of the transplanted cells in the metachromatic leukodystrophy trial and 25% to 50% in the Wiskott-Aldrich trial produced the desired proteins, and continued to do so throughout roughly two years of follow-up.

That marked a major leap from a 2009 trial that used a similar approach to treat adrenoleukodystrophy, another degenerative disease. In that study, 15% of cells made the normal enzyme over the same time period.

Dr. Luigi Naldini, a scientist at the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy, who helped lead the trials, said his team fine-tuned the viral delivery method that had been pioneered in the 2009 study. Using the HIV-derived lentivirus was safer than relying on the mouse retroviruses tested in earlier gene therapy trials, because lentiviruses are less likely to activate cancer-causing genes near the target gene on a chromosome.

Naldini and his colleagues optimized the lentiviral techniques further, lessening cancer risk by tracking each modified stem cell — and its daughter cells — over time, and figuring out ways to grow purer, more concentrated lentivirus and to introduce the desired genes into cells more efficiently.

The group also fine-tuned their ability to wipe out enough resident bone marrow stem cells to make room for the modified cells, but not enough to have toxic effects.

Dr. Jennifer Puck, a pediatrician at UC San Francisco who was not involved in the research, praised the Italian team for getting such good results, even while incorporating safety modifications that tend to make such therapies less effective.

She cautioned, though, that the findings were still preliminary and that knowing whether the patients would remain free of immune deficiencies, cancer or neurological defects would take more than just a few years of follow-up.

Dr. Donald Kohn, a pediatric gene therapist at UCLA, who also wasn't involved in the study, said researchers may be able to use the team's method of delivering an HIV-packaged gene through patients' bone marrow stem cells as a template for treating a variety of diseases.

Besides about 50 other blood cell genetic disorders, such as sickle cell anemia, the therapy may also be adapted to AIDS, leukemia and other diseases involving the blood and immune cells that arise from bone marrow stem cells, he said.

melissa.pandika@latimes.com

Copyright © 2013, Los Angeles Times







747    "여성 X염색체에 정자생산 관여 유전자 존재"  이성욱 2013/07/23 2220
746   다운증후군 원인 염색체 침묵화 가능성 확인  이성욱 2013/07/22 2255
745   Stem cells reprogrammed using chemicals alone  이성욱 2013/07/20 2082
744   Scientists find way to silence extra chromosome that causes Down syndrome  이성욱 2013/07/20 2212
  Gene therapy using HIV helps children with fatal diseases, study says  이성욱 2013/07/16 2017
742   Scientists develop ground-breaking new method of 'starving' cancer cells  이성욱 2013/07/15 2340
741   암 전이(metastasis)로 통하는 문을 공략하라  이성욱 2013/07/09 2377
740   줄기세포 이식으로 HIV 감염 완치: 세계 3번째, 4번째의 HIV 완치 환자 등장  이성욱 2013/07/05 2839
739   줄기세포로 사람 '肝씨앗' 만들어 자라게… 日 세계 첫 성공  이성욱 2013/07/04 2193
738   ‘젊은 유전자’로 안티에이징.. 파괴적 혁신 기술이 미용·항노화산업 발달 촉진  이성욱 2013/07/01 3114
737   생물학적 주기 및 대사 유전자의 간섭과 연관되어 있는 프라더-윌리 증후군  이성욱 2013/06/28 3235
736   日, 유도만능줄기세포 임상연구 세계 최초 승인  이성욱 2013/06/27 2257
735   복제연구를 둘러싼 논쟁  이성욱 2013/06/21 2038
734   유전자 특허 불인정 판결의 후폭풍: 멘붕에 빠진 미 BT 업계  이성욱 2013/06/20 2922
733   Biotech industry worries over Supreme Court DNA ruling  이성욱 2013/06/15 2224
732   Potential New Target to Thwart Antibiotic Resistance: Viruses in Gut Confer Antibiotic Resistance to Bacteria  이성욱 2013/06/13 2258
731   장내 미생물균총 변화로 당뇨 예측  이성욱 2013/06/07 2491
730   인헨서의 역할과 인헨서 치료법  이성욱 2013/06/07 2346
729   결핵, 탄저병, 세균성 이질 등에 보다 효과적인 새로운 종류의 항생제 개발  이성욱 2013/06/06 2385
728   미탈리포프 이후, 변화의 조짐을 보이는 미국의 줄기세포 연구환경  이성욱 2013/06/06 2433

[이전 10개] [1]..[21][22][23][24][25][26] 27 [28][29][30]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN